Small-cell lung cancer accounts for about 10%-15% of all lung cancers, yet its molecular pathogenesis remains largely ...

It was in with the new and out with the old Jan. 3 as the gavel came down on the first session of the 119th U.S. Congress.

The device industry is extraordinarily dependent on administrative activity where Medicare coverage is concerned, and this ...

Altamira Therapeutics Ltd.’s nanoparticle-based delivery platform has been successfully tested for circular mRNA.

Already hot for years, antibody-drug conjugates (ADCs) continued to hold charm for the industry, sparking a number of sizable ...

The Asia Pacific med-tech market is projected to reach $140 billion in 2025 in value, growing roughly 5% per year, driven ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for ...

Ausperbio Therapeutics Inc. raised $110 million from two financing rounds in 2024 to advance its lead antisense ...

Companies working in the field of women’s health have long struggled for funding, but as the number of these companies increase and new dedicated venture capital funds emerge, the conversation is ...

Daiichi Sankyo Co. Ltd.’s trophoblast cell surface antigen 2 (Trop2)-directed antibody-drug conjugate (ADC), datopotamab ...

The U.K. is embarking on the biggest overhaul of clinical trials regulations in 20 years in a bid to retake ground that was lost following Brexit, when the Medicines and Healthcare products Agency was ...

Toll-like receptors (TLRs) are crucial to trigger anticancer immune responses. Despite the promise of TLR agonists as potential anticancer agents, few have reached the clinics due to concerns related ...